(Q35629777)

9 August 2017

Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents (English)

1 reference

9 August 2017

1 reference

1 reference

1 reference

1 reference

8

Saïk Urien

0 references

Jean-Marc Tréluyer

7

object named as

Jean-Marc Treluyer

0 references

Catherine Dollfus

3

object named as

Catherine Dollfus

0 references

author name string

Frantz Foissac

1

1 reference

9 August 2017

Stéphane Blanche

2

1 reference

9 August 2017

Catherine Dollfus

3

1 reference

9 August 2017

Déborah Hirt

4

1 reference

9 August 2017

Ghislaine Firtion

5

1 reference

9 August 2017

Corinne Laurent

6

1 reference

9 August 2017

Jean-Marc Treluyer

7

1 reference

9 August 2017

Saïk Urien

8

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 December 2011

1 reference

British Journal of Clinical Pharmacology

9 August 2017

1 reference

9 August 2017

72

1 reference

9 August 2017

6

1 reference

9 August 2017

940-947

1 reference

Correlations between atazanavir C(trough )and hyperbilirubinemia: a case report

9 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3244641

Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3244641

Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3244641

Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3244641

Likelihood based approaches to handling data below the quantification limit using NONMEM VI.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3244641

Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3244641

Mechanism-based concepts of size and maturity in pharmacokinetics

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3244641

Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3244641

Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3244641

Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3244641

Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study

27 July 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04035.X

Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04035.X

Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE st

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04035.X

96-week efficacy and safety of atazanavir, with and without ritonavir, in a HAART regimen in treatment-naive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04035.X

Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsules or amprenavir in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04035.X

Population pharmacokinetics of atazanavir in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04035.X

Change to a once-daily combination including boosted atazanavir in HIV-1-infected children

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21649692

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21649692

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1111/J.1365-2125.2011.04035.X

1 reference

9 August 2017

1 reference

9 August 2017

1 reference